Skip to content
Open access · US-GOV via ClinicalTrials.gov Clinical trial

SGLT2 Inhibition as a Therapeutic Strategy to Reverse Arterial Stiffening in Aging

Authors not listed

University of Missouri-Columbia · 2024

Abstract

Randomized placebo-controlled clinical trial in a cohort of males (n=40) and females (n=40), 60-80 years of age, with the hypothesis that SGLT2 inhibition with empagliflozin (10mg/day for 12 weeks) reduces aging-related arterial stiffening.

◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:

Read at source →

Provenance

Source
ClinicalTrials.gov
Canonical
link ↗
Fetched
2026-10-23 MST

Cite this

APA
Anonymous. (2024). SGLT2 Inhibition as a Therapeutic Strategy to Reverse Arterial Stiffening in Aging. <em>University of Missouri-Columbia</em>. https://clinicaltrials.gov/study/NCT06506422
Vancouver
Anonymous. SGLT2 Inhibition as a Therapeutic Strategy to Reverse Arterial Stiffening in Aging. University of Missouri-Columbia. 2024.
BibTeX
@misc{anon2024SGLTIn, title = {SGLT2 Inhibition as a Therapeutic Strategy to Reverse Arterial Stiffening in Aging}, author = {Anonymous}, journal = {University of Missouri-Columbia}, year = {2024}, }

Research neighborhood

References, citing works, and semantically nearest findings. Click a node to open it.

Related findings